Brexit impact on UK pharma industry a moveable feast, industry experts tell CPhI Discover
The UK’s withdrawal from the European Union has meant the pharmaceutical industry has had to adapt to some monumental changes in terms of research, regulatory affairs, and trade.
May 21, 2021
by cphi-online
Post-Brexit point-based immigration system will affect the UK’s healthcare system: Poll
The UK government commenced taking applications for the new Skilled Worker Visa from January 2021, based on the new post-Brexit points-based visa and immigration system.
April 16, 2021
by pharmaceutical-technology
Cross-EU drug supply chain to be most affected post Brexit: Poll
The UK’s decision to opt out of the European Union (EU) has set numerous industries up for disruptions especially after the official exit in January 2020.
January 22, 2021
by pharmaceutical-technology
Pharma urged to review anti-counterfeiting strategies ahead of no-deal Brexit
According to various associations, the UK could experience a high influx of counterfeit medicines if it leaves the EU without a deal.
October 29, 2020
by europeanpharmaceuticalreview
ABPI chief exec says no-deal Brexit is ‘not in the interest of patients’
Following prime minister Boris Johnson’s announcement last week that he was preparing for a no-deal with the EU, the Association for the British Pharmaceutical Industry (ABPI) has warned against such an outcome.
October 21, 2020
by pharmatimes
COVID-19 to influence the outcome of Brexit: Poll
The Brexit transition deadline of 31 December 2020 is fast approaching, but a trade deal between the UK and European Union (EU) is yet to be finalised.
October 15, 2020
by pharmaceutical-technology
Medicine suppliers in UK urged to stockpile in preparation for end of Brexit transition period
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.
August 5, 2020
by europeanpharmaceuticalreview
Evolving World of Pharma: Defining the precise impact of Brexit?
Shortly ahead of the delayed exit deadline of January 31st, it was already clear that – in the UK in particular – Brexit was going to have an impact this year.
January 31, 2020
by Sarah Harding
Pharma bodies confirm signing NDAs for no-deal Brexit plans
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
August 16, 2019
by europeanpharmaceuticalreview
Is the pharma sector ready for a ‘no-deal’ Brexit?
Is the pharma sector ready for a ‘no-deal’ Brexit?
May 17, 2019
by europeanpharmaceuticalreview
Brexit's trick or treat on patient safety
Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.
May 5, 2019
by cphi-online
Pharma firms step up plans to beat Brexit supply chain disruption
The EMA has revised downwards the number of medicines expected to face Brexit-related supply disruptions from 108, earlier this year, to a current level of 39…
April 19, 2019
by europeanpharmaceuticalreview